What was the primary driver for the year-over-year revenue decrease in the third quarter?

The primary driver for the revenue decrease in the third quarter of 2022 was a significant decline in sales of Comirnaty (the Pfizer-BioNTech COVID-19 vaccine). This decrease was partially offset by strong growth from Paxlovid, the company's oral COVID-19 treatment.

How have recent acquisitions impacted Pfizer's financial position and future outlook?

Pfizer made significant acquisitions, including Arena Pharmaceuticals for $6.6 billion and Biohaven for $11.5 billion. These acquisitions are expected to strengthen Pfizer's product pipeline, particularly in areas like immuno-inflammatory diseases and migraine treatments, contributing to future growth and diversifying revenue streams beyond COVID-19 products.

What is Pfizer's outlook for its COVID-19 products, Comirnaty and Paxlovid, for the remainder of 2022?

Pfizer forecasts approximately $34 billion in revenues for Comirnaty and $22 billion for Paxlovid for the full year 2022. These projections are based on existing supply contracts and expected deliveries, though they remain subject to market dynamics and future contract renewals.

How is Pfizer managing R&D investments in light of its acquisitions and pipeline development?

Pfizer increased its R&D expenses in the first nine months of 2022, primarily driven by costs associated with developing recently acquired assets and ongoing investments in late-stage clinical programs for both COVID-19 and non-COVID-19 indications. This demonstrates a continued commitment to innovation and pipeline advancement.

PFE 10-Q Filed Nov 9, 2022

Summary

Pfizer Inc. reported revenues of $22.6 billion for the third quarter of 2022, a 6% decrease year-over-year, primarily driven by lower sales of Comirnaty, partially offset by growth from Paxlovid. For the first nine months of 2022, revenues increased by 32% to $76.0 billion, largely due to strong performance from Paxlovid and Comirnaty. Net income attributable to Pfizer Inc. common shareholders was $8.6 billion for the quarter, up from $8.1 billion in the prior year. The company completed significant acquisitions, including Arena Pharmaceuticals for $6.6 billion and Biohaven for $11.5 billion, which are expected to bolster its pipeline. Despite a decrease in Comirnaty sales, Pfizer's overall financial health remains strong, supported by diversified product offerings and strategic business development. The company's liquidity position is robust, with significant operating cash flows and access to credit facilities. Pfizer continues to invest in research and development, with a notable increase in R&D expenses driven by the development of newly acquired assets and ongoing late-stage clinical programs. Investors should monitor the ongoing patent litigations and regulatory developments, particularly concerning the impact of the Inflation Reduction Act on drug pricing.

Key Highlights

1Total revenues for Q3 2022 decreased 6% to $22.6 billion, primarily due to lower Comirnaty sales, though offset by growth in Paxlovid.
2Nine-month revenues increased 32% to $76.0 billion, driven by strong performance from Paxlovid and Comirnaty.
3Net income attributable to common shareholders was $8.6 billion for Q3 2022, an increase from $8.1 billion in Q3 2021.
4The company completed significant acquisitions, including Arena Pharmaceuticals for $6.6 billion and Biohaven for $11.5 billion, enhancing its pipeline.
5Research and Development expenses increased in the first nine months of 2022, reflecting investments in acquired assets and late-stage clinical programs.
6Despite challenges, Pfizer maintains a strong liquidity position with robust operating cash flows and available credit facilities.
7The company forecasts approximately $34 billion in Comirnaty revenues and $22 billion in Paxlovid revenues for the full year 2022.

PFIZER INC Quarterly Report for Q3 Ended Oct 2, 2022

Summary

Key Highlights

Frequently Asked Questions